Pei-Ling Chen,Whijae Roh,Alexandre Reuben,Zachary A. Cooper,Christine N. Spencer,Peter A. Prieto,John P. Miller,Roland L. Bassett,Vancheswaran Gopalakrishnan,Khalida Wani,Mariana Petaccia de Macêdo,Jacob L. Austin-Breneman,Hong Jiang,Qing Chang,Sangeetha M. Reddy,Wei-Shen Chen,Michael T. Tetzlaff,Russell Broaddus,Michael A. Davies,Jeffrey E. Gershenwald,Lauren E. Haydu,Alexander J. Lazar,Sapna P. Patel,Patrick Hwu,Wen‐Jen Hwu,Adi Diab,Isabella C. Glitza,Scott E. Woodman,Luis M. Vence,Ignacio I. Wistuba,Rodabe N. Amaria,Lawrence N. Kwong,Víctor G. Prieto,R. Eric Davis,Wencai Ma,Willem W. Overwijk,Arlene H. Sharpe,Jianhua Hu,P. Andrew Futreal,Jorge Blando,Padmanee Sharma,James P. Allison,Lynda Chin,Jennifer A. Wargo

Abstract:Supplementary Figure 1. Immune profiling of pre-treatment, on-treatment and progression CTLA-4 blockade samples by immunohistochemistry. Supplementary Figure 2. Myeloid cell profiling of pre-treatment, on-treatment and progression CTLA-4 blockade samples by immunohistochemistry. Supplementary Figure 3. Increased contact between CD8 T cells and CD68 myeloid cells in non-responding patients to anti-CTLA-4 and anti-PD-1 therapy at pre-treatment CTLA-4 blockade, pre-treatment PD-1 blockade, and on-treatment PD-1 blockade time points. Supplementary Figure 4. Immune profiling of pre anti-PD-1, on-treatment anti-PD-1 and progression anti-PD-1 samples by immunohistochemistry. Supplementary Figure 5. Longitudinal increase in CD8, PD-1, and PD-L1 expression in responders to anti-PD-1 therapy. Supplementary Figure 6. Relative increase in CD8 T cell infiltrate at tumor center in responders to anti-PD-1 on treatment. Supplementary Figure 7. Significant increase in immune infiltrate between responders and non-responders to PD-1 blockade in absence of prior anti-CTLA-4 therapy. Supplementary Figure 8. Immune profiling of myeloid cells atpre-treatment and on-treatment PD-1 blockade time pointsby immunohistochemistry. Supplementary Figure 9. Heatmap of 54 NanoString samples. Supplementary Figure 10. Gene-specific NanoString concordance with immune profiling by IHC in pre-treatment, on-treatment and progression CTLA-4 blockade samples. Supplementary Figure 11. Gene-specific NanoString concordance with immune profiling by IHC in pre-treatment, on-treatment and progression PD-1 blockade samples. Supplementary Figure 12. Prior CTLA-4 blockade is not required for PD-1 early on-treatment profile. Supplementary Figure 13. Hierarchical clustering of gene expression across 54 samples confirms lack of batch effect.

Supplementary Data from Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy

Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Supplementary Data from Spatial Organization and Prognostic Significance of NK and NKT-like Cells Via Multimarker Analysis of the Colorectal Cancer Microenvironment

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Supplementary Data from Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC

Supp. Tables S16-S19 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplementary Data from Efficient Tumor Clearance and Diversified Immunity Through Neoepitope Vaccines and Combinatorial Immunotherapy

Supplementary Table S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Supplementary Table 1 from Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colorectal Cancer

Supplementary Figure Legends from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Supplementary Table 1 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver Versus Lung Metastases

Supplementary Table S8 from CD38-Mediated Immunosuppression As a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Supplementary Data from Genetically Defined Syngeneic Mouse Models of Ovarian Cancer As Tools for the Discovery of Combination Immunotherapy

Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma

Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary Figures 1 - 13 from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Supplementary Figure S6 from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[<sup>18</sup>F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect